Literature DB >> 11797012

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.

Dan H Barouch1, Jennifer Kunstman, Marcelo J Kuroda, Jörn E Schmitz, Sampa Santra, Fred W Peyerl, Georgia R Krivulka, Kristin Beaudry, Michelle A Lifton, Darci A Gorgone, David C Montefiori, Mark G Lewis, Steven M Wolinsky, Norman L Letvin.   

Abstract

Potent virus-specific cytotoxic T lymphocyte (CTL) responses elicited by candidate AIDS vaccines have recently been shown to control viral replication and prevent clinical disease progression after pathogenic viral challenges in rhesus monkeys. Here we show that viral escape from CTL recognition can result in the eventual failure of this partial immune protection. Viral mutations that escape from CTL recognition have been previously described in humans infected with human immunodeficiency virus (HIV) and monkeys infected with simian immunodeficiency virus (SIV). In a cohort of rhesus monkeys that were vaccinated and subsequently infected with a pathogenic hybrid simian-human immunodeficiency virus (SHIV), the frequency of viral sequence mutations within CTL epitopes correlated with the level of viral replication. A single nucleotide mutation within an immunodominant Gag CTL epitope in an animal with undetectable plasma viral RNA resulted in viral escape from CTLs, a burst of viral replication, clinical disease progression, and death from AIDS-related complications. These data indicate that viral escape from CTL recognition may be a major limitation of the CTL-based AIDS vaccines that are likely to be administered to large human populations over the next several years.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11797012     DOI: 10.1038/415335a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  242 in total

1.  Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.

Authors:  Sampa Santra; Dan H Barouch; Marcelo J Kuroda; Jörn E Schmitz; Georgia R Krivulka; Kristin Beaudry; Carol I Lord; Michelle A Lifton; Linda S Wyatt; Bernard Moss; Vanessa M Hirsch; Norman L Letvin
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.

Authors:  SangKon Oh; Jay A Berzofsky; Donald S Burke; Thomas A Waldmann; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

Review 3.  Strategies for an HIV vaccine.

Authors:  Norman L Letvin
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

4.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.

Authors:  Xu G Yu; Marylyn M Addo; Eric S Rosenberg; William R Rodriguez; Paul K Lee; Cecily A Fitzpatrick; Mary N Johnston; Daryld Strick; Philip J R Goulder; Bruce D Walker; Marcus Altfeld
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level.

Authors:  Golo Ahlenstiel; Kirsten Roomp; Martin Däumer; Jacob Nattermann; Martin Vogel; Jürgen K Rockstroh; Niko Beerenwinkel; Rolf Kaiser; Hans-Dieter Nischalke; Tilman Sauerbruch; Thomas Lengauer; Ulrich Spengler
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.

Authors:  John R Mascola; Mark G Lewis; Thomas C VanCott; Gabriela Stiegler; Hermann Katinger; Michael Seaman; Kristin Beaudry; Dan H Barouch; Birgit Korioth-Schmitz; Georgia Krivulka; Anna Sambor; Brent Welcher; Daniel C Douek; David C Montefiori; John W Shiver; Pascal Poignard; Dennis R Burton; Norman L Letvin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.

Authors:  Tatsuhiko Igarashi; Yasuyuki Endo; Yoshiaki Nishimura; Charles Buckler; Reza Sadjadpour; Olivia K Donau; Marie-Jeanne Dumaurier; Ronald J Plishka; Alicia Buckler-White; Malcolm A Martin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.